214 The KRASG12D(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRASG12D mutant cancer

• Nataliya Tovbis Shifrin,
• Marie Menard,
• Haley Courtney,
• Swetha Ganesh,
• Alice Kumamoto,
• Lillian Seu,
• Jacqueline AM Smith,
• Elsa Quintana

Affiliations

Nataliya Tovbis Shifrin

Revolution Medicines, Redwood City, CA, USA

Marie Menard

Revolution Medicines, Redwood City, CA, USA

Haley Courtney

Revolution Medicines, Redwood City, CA, USA

Swetha Ganesh

Revolution Medicines, Redwood City, CA, USA

Alice Kumamoto

Revolution Medicines, Redwood City, CA, USA

Lillian Seu

Revolution Medicines, Redwood City, CA, USA

Jacqueline AM Smith

Revolution Medicines, Redwood City, CA, USA

Elsa Quintana

Revolution Medicines, Redwood City, CA, USA